CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...
United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...
MyChesCo on MSN5d
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The ...
BioXcel Therapeutics Provides Clinical and Business Update
Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...
Mineralys completes enrollment for hypertension drug trial
RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...